Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2005

View Archived Issues

Allopregnanolone shows efficacy in a rat model of spontaneous recurrent seizures

Analogues of etodolac from Salmedix for MM

A3R agonism effective for cholangiocarcinoma

Trend toward positive survival benefit in patients treated with Zadaxin plus TACE

BioCryst cleared to study intravenous peramivir in phase I

Updated antibacterial efficacy of tebipenem pivoxil presented at ICAAC

New phase I/II trial of intravenous Fodosine in B-cell ALL

SPA agreement for phase III study of ramoplanin

Sirna selects Sirna-AV34 as development candidate for hepatitis C

Exelixis and Wyeth sign licensing agreement for compounds targeting FXR

Japanese approval for expanded use of Peg-Intron and Rebetol in HCV

Genzyme acquires gene therapy assets from Avigen

FTC clearance for Roche's licensing of BCX-4208

AtheroGenics and AstraZeneca sign agreement for AGI-1067

Bristol-Myers Squibb and Merck & Co. terminate muraglitazar agreement

Sinovac begins clinical testing of Panflu H5N1 vaccine

Enrollment update for AI-700 phase III program

Approval letter for Biovail's ODT formulation of citalopram hydrobromide

Orphan drug designation for eniluracil in liver cancer

Wyeth submits NDA for desvenlafaxine extended release

CT-32228 shows promise for treatment of imatinib-resistant CML

Phase II Cloretazine data presented

Quinoline and benzimidazole derivatives as potential candidates for presymptomatic diagnosis of AD

New D3 receptor antagonist exhibits antipsychotic properties in models of schizophrenia

Recent patents report novel analgesic agents

New therapeutic agents for skin disorders disclosed in recent Galderma patent

Recent patents report new therapeutic agents for diabetes and other endocrine-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...